Impact of positive surgical margins on overall survival after partial nephrectomy—A matched comparison based on the National Cancer Database by Shum, Cheuk Fan et al.
1 
Impact of Positive Surgical Margins on Overall Survival after Partial Nephrectomy, 
a Matched Comparison Based on the National Cancer Database 
Authors 
• Cheuk Fan Shum
Department of Urology, Indiana University School of Medicine, Indianapolis, IN
46202
Email: shum.cheuk.fan@ktph.com.sg
• Clinton D. Bahler
Department of Urology, Indiana University School of Medicine, Indianapolis, IN
46202
Email: cdbahler@iupui.edu
• Chandru P. Sundaram
Department of Urology, Indiana University School of Medicine, Indianapolis, IN
46202
Email: sundaram@iupui.edu
Details of corresponding author 
Name: Chandru P. Sundaram 
Affiliation: Department of Urology, Indiana University School of Medicine 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Shum, C. F., Bahler, C. D., & Sundaram, C. P. (2018). Impact of positive surgical margins on overall survival after 
partial nephrectomy—A matched comparison based on the National Cancer Database. Urologic Oncology: 
Seminars and Original Investigations, 36(3), 90.e15-90.e21. https://doi.org/10.1016/j.urolonc.2017.11.009
2 
 
Postal address: 535 N Barnhill Dr, Suite 420, Indianapolis, IN 46202-5289, United 
States 
Email: sundaram@iupui.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Highlights 
• Using the National Cancer Database, we performed a matched comparison 
between positive and negative surgical margins after partial nephrectomy for 
localized renal cell carcinoma. 
• Patients with positive surgical margins in partial nephrectomy have significantly 
worse overall survival. 
• Old age, high comorbidity score and large tumor size are also associated with 
higher hazard ratios for all-cause mortality, while papillary and chromophobe 
histology subtypes have lower hazard ratios. 
 
Introduction 
The impact of positive surgical margins (PSM) in partial nephrectomy (PN) has been a 
controversy. Previous studies on the relationship between PSM and overall survival (OS) 
were either underpowered or had highly dissimilar groups. We used the National 
Cancer Database with propensity score matching to determine the association between 
PSM and OS after PN. 
 
Materials and Methods 
We identified patients with T1/T2N0M0 renal cancer treated with PN between 2004 and 
2009, and divided them into 2 groups based on their margin status. We used propensity 
score matching to ensure similarities in age, comorbidity score (CCI), tumor size, 
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histology and grade between groups. Covariates were compared by χ2 test. Cox 
multiple regression was used to estimate the hazard ratios (HR) for all-cause mortality. 
OS between matched groups were compared by log-rank, Breslow and Tarone-Ware 
tests. 
 
Results 
After excluding those with missing data on margin or survival status, 20762 patients 
were eligible for matching. Each matched group had 1265 patients, similar in age, 
gender, race, CCI, tumor size, histology and grade. There were 386 recorded all-cause 
mortalities over a median follow-up duration of 72.6 months. Cox multiple regression 
showed a higher risk of all-cause mortality among cases with PSM (HR: 1.393, p=0.001). 
Old age, high CCI and large tumors had higher risks, while papillary and chromophore 
histologic subtypes had lower risks. PSM was associated with significantly worse OS by 
log-rank, Breslow and Tarone-Ware tests. 
 
Conclusion 
PSM is associated with significantly worse OS after PN. 
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Introduction 
The impact of positive surgical margins (PSM) in partial nephrectomy (PN) has been a 
controversy. Various studies showed conflicting results regarding the associations 
between PSM and progression-free,1 – 7 cancer-specific,5, 8, 9 as well as overall survivals 
(OS).5, 8, 10 A multi-centered study5 and a study based on the Ontario Cancer Registry8 
found no associations between PSM and OS, but the statistical powers of both studies 
were limited by small sample sizes. A more recent study based on the National Cancer 
Database (NCDB) involved a cohort of 6038 patients who underwent PN for clinical T1 
or T2 disease, and found PSM to be associated with an increased risk of all-cause 
mortality.10 However, the PSM group in this study had significantly older patients with 
higher comorbidity scores compared to the negative surgical margins (NSM) group, so 
there might be confounding effects from other covariates. To determine the association 
between PSM and OS, a study that has a large sample size yet similar groups for 
comparison would be ideal. 
Therefore, we used the latest NCDB participant user file (PUF) to determine if PSM has 
an impact on OS after PN in the contemporary clinical setting, with statistical matching 
to ensure similarities in key covariates between groups. 
 
Materials and Methods 
The institutional review board approved this study (protocol number: 1611211043, 
approval date: December 7, 2016). 
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We used the NCDB PUF spanning from 2004 to 2014. To ensure that all cases for 
analysis had a minimum of 5 years of follow-up after PN, we only included cases 
between 2004 and 2009. Patients with renal cell carcinoma (RCC) were identified as 
those who carried the code C649 for the data item ‘Primary Site’, based on the 
International Classification of Diseases for Oncology, 3rd Edition.11 Among these cases, 
we selected those with clinical T1 or T2 N0M0 disease according to data items ‘AJCC 
Clinical T’, ‘AJCC Clinical N’ and ‘AJCC Clinical M’, based on the American Joint 
Committee on Cancer Stage Manual, 7th Edition.12 The cases were screened to identify 
those treated with PN, according to the data item ‘Surgical Procedure of the Primary 
Site at any CoC Facility’ with the code 30 representing PN, and were classified into two 
groups based on surgical margin status. Duration of follow-up was defined by the data 
item ‘’Last Contact or Death, Months from Dx’ as the time between the date of initial 
diagnosis and the date on which the patient was last contacted or died, and survival 
status at the end of follow-up was defined by the data item ‘PUF Vital Status’. Patients 
with missing data on surgical margin status or survival status were excluded. 
The endpoint of our study was OS in the PSM and NSM groups. Covariates included 
age, gender, race, Charlson-Deyo comorbidity score (CCI), tumor size, histology and 
grade. Figure 1 summarizes the process of patient selection prior to statistical matching. 
We recoded ratio covariates into clinically meaningful categories for statistical analysis. 
We first performed multivariate logistic regression to identify predictors for PSM. This 
was followed by propensity score matching with fuzz factor set at 0, giving priority to 
exact matches and without replacement in sampling, to produce a PSM and a NSM 
group with matches for age, CCI, tumor size, histology and grade. Covariates were 
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compared between groups by χ2 test, with relevant Cramer’s V values to reflect effect 
sizes. Cox multiple regression was then used to estimate the hazard ratios (HR) of the 
covariates for all-cause mortality. Log-rank, Breslow and Tarone-Ware tests were used 
to compare OS between matched groups. Further analyses were done among patients 
of specific age or with specific CCI, tumor size, histology and grade to determine the 
effects of PSM in these subgroups. All statistical analyses were done using SPSS 
version 24.0 (IBM Corp., Armonk, NY). A p value of <0.05 defined statistical significance 
throughout the study. 
 
Results 
A total of 21243 patients with T1 or T2 N0M0 RCC between 2004 and 2009 underwent 
PN. Among them, 475 patients had unknown surgical margin status and were excluded. 
Of the remaining 20768 patients, 1279 had PSM and 19489 had NSM. One patient from 
the PSM group and 5 patients from the NSM group were excluded due to missing data 
on survival status. Therefore, 1278 PSM and 19484 NSM patients were eligible for 
statistical matching. Propensity score matching produced two groups highly similar in 
age, gender, race, CCI, tumor size, histology and grade, with 1265 patients in each 
group. Table 1 illustrates the descriptive statistics before and after statistical matching. 
Compared to the reference category of age below 50 years, most other categories of 
age had statistically significant odds ratios (OR) above 1 for PSM. Increasing age 
appeared to be associated with higher odds for PSM, with OR up to 1.800 among those 
aged 80 years and above. Papillary and chromophobe tumors, as well as Fuhrman 
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grade 3 or 4 tumors, also had statistically significant OR above 1 for PSM compared to 
their respective reference categories. Table 2 illustrates the multivariate logistic 
regression model estimating the ORs for PSM among the various categories of 
covariates in our study. 
After matching, the mean follow-up duration was 70.3 months (median: 72.6 months), 
with 386 recorded all-cause mortality. Cox multiple regression showed that PSM was 
associated with a higher risk of all-cause mortality compared to NSM (HR: 1.393, 
p=0.001). There was a clear trend showing increasing risks of all-cause mortality 
proportional to age. Compared to tumors 4cm and below, tumors above 4cm up to 7cm 
and tumors above 7cm up to 10cm were associated with increased risks of all-cause 
mortality (HR: 1.592, 2.639; p<0.001, =0.003 respectively). Tumors above 10cm had a 
HR of 3.548 though this was not statistically significant, likely due to the very low 
numbers within this category after matching. Compared to CCI of 0, CCI of 1 was not 
associated with a significantly higher risk of all-cause mortality, while CCI of 2 and 
above had a statistically significant HR of 2.384 (p<0.001). 
With reference to clear cell RCC, papillary and chromophobe tumors were associated 
with decreased risks of all-cause mortality (HR: 0.719, 0.341; p=0.020, <0.001 
respectively). Sarcomatoid tumors had a HR of 1.724 though this was not statistically 
significant, again likely due to the very low numbers within this category after matching. 
Gender, race and tumor grade did not seem to have significantly different HRs for all-
cause mortality compared to their respective reference categories. Table 3 illustrates 
the Cox multiple regression model estimating the HRs for all-cause mortality among the 
various categories of covariates in our study. 
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Log-rank, Breslow and Tarone-Ware tests showed significantly worse OS in patients 
with PSM compared to those with NSM, with p-values of 0.003, 0.011 and 0.006 
respectively. Figure 2 represents the Kaplan-Meier curves for OS stratified by surgical 
margin status. 
PSM appeared to have significantly adverse impact on OS among patients aged 70 
years and above, with CCI of 1, tumor size 4cm and below and clear cell RCC. It also 
exerted adverse impacts on OS across all categories of tumor grades. Table 4 
illustrates the HRs for all-cause mortality due to PSM among patients in specific 
subgroups of age, CCI, tumor size, histology and grade, with reference to those with 
NSM in the same subgroups. 
 
Discussion 
The basis of PN is nephron preservation, which is associated with improved post-
operative renal function, reduced renal and cardiovascular complications and better 
OS.13, 14 On the oncologic aspect, PN has an incidence of PSM ranging from 0 to 7%,15 
which is much higher than that of radical nephrectomy.16 Nonetheless, PN has 
surpassed RN as the standard surgical option for most localized renal tumors.17, 18 
The clinical impact of PSM in PN has been a controversy. Various multi-centered 
studies have made conflicting conclusions on whether PSM results in an increased risk 
of tumor recurrence.1 – 3, 5, 6 Interestingly, most studies found no impact on cancer-
specific survival by PSM.5, 8, 9 It is possible that PSM is associated with increased tumor 
recurrence without compromising cancer-specific survival due to the slow growth rate of 
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any microscopic residual tumor cells, since the mean annual growth rate of 
radiologically evident small renal masses is about 0.28cm.19 It takes a long time for any 
recurrences to be clinically detectable, and an even longer time to cause cancer-related 
mortality. 
A long duration between PN and any subsequent deaths implies that such mortality is 
prone to various clinical and non-clinical factors beyond cancer related ones. As such, 
without discounting the clinical importance of other survivals, OS should also be 
regarded as one of the more relevant quality control measures after PN. Our study does 
not include progression-free and cancer-specific survivals as endpoints, due to 
limitations of the NCDB, but our finding of PSM being associated with a higher risk of 
all-cause mortality emphasizes the clinical need to reduce PSM at all cost during PN, 
amidst the various reports that PSM does not affect tumor recurrence and cancer-
specific survival.1, 4, 5, 6, 8, 9 
Prior to our findings, only one other study found PSM to have significant impact on OS 
after PN.10 This study by Maurice MJ et al was also based on the NCDB and included 
patients with clinical T1 or T2 N0M0 RCC treated with PN between 2003 and 2006. 
They found that PSM had a statistically significant HR of 1.35 for all-cause mortality. 
However, their initial univariate analysis showed that patients in the PSM group were 
significantly older with higher CCI. The tumors in their PSM and NSM groups were also 
significantly different in pathologic T-stage. The authors then performed multivariate 
logistic regressions analyses, which showed that CCI and pathologic T-stage were 
associated with both PSM and OS. These associations raised the possibility of 
significant confounding by CCI and pathologic T-stage when they drew the conclusion 
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that PSM was associated with poorer OS. Their findings prompted us to re-assess the 
statistical approach towards making comparisons using data from the NCDB. 
The occurrence of PSM in PN is associated with various clinical factors. The multi-
centered Registry of Conservative Renal Surgery project by 19 Italian urology centers 
found increased risks of PSM in patients who were older, with upper pole tumors or with 
Fuhrman grade 3 or 4 tumors.20 Similarly, our study found that older patients and those 
with Fuhrman grade 3 or 4 tumors had increased risks for PSM. The Surveillance and 
Treatment Update Renal Neoplasms study found an increased risk of PSM in PN 
compared to simple enucleation in univariate analysis. However, its PN group consisted 
of patients with larger and higher grade tumors, treated by institutions with lower 
caseloads, and no further analysis was done to reduce confounding.21 Kwon EO et al 
found imperative indication for PN to be the only significant factor associated with an 
increased risk of PSM in their multivariate analysis,7 though this may not be clinically 
relevant since PN indications are no longer classified into ‘absolute’, ‘relative’ and 
‘elective’. Ani I et al found perinephric fat invasion to be a significant factor for PSM, but 
pathologic T3-stage tumors did not have statistically significant increased HR in the 
same multivariate logistic regression model.8 Our finding that papillary and 
chromophobe tumors had increased risks for PSM compared to clear cell RCC 
appeared counter-intuitive. Without further details on the use of pre-operative biopsy 
and the proportion of cases treated by enucleation, it was difficult to pinpoint why certain 
histologic subtypes had increased PSM risks. 
Based on the findings of these studies, we decided that statistical matching should be 
performed for age, CCI, tumor size, histology and grade. Since the NCDB does not 
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contain information like surgical approach, tumor configuration and nephrometry scores, 
these could not be matched. Nonetheless, propensity score matching resulted in high 
similarities between our PSM and NSM groups, with perfect matches in key covariates 
like age, CCI, tumor size, histology and grade. 
Subgroups analyses in our study found that OS in certain categories of patients, such 
as the elderly, those with clinical T1a tumors and clear cell RCC, are especially prone to 
the adverse impacts of PSM. Interestingly, while Cox multiple regression did not find a 
higher HR for all-cause mortality in high grade tumors compared to low grade ones, 
subgroup analyses revealed that PSM exerted adverse impacts on OS across all tumor 
grades. This highlights the importance to avoid PSM even if pre-operative imaging 
describes a localized small renal mass or pre-operative biopsy suggests a low grade 
tumor. Such importance is also applicable among elderly patients, despite the common 
belief that many of these patients may die with RCC rather than from RCC when there 
is residual tumor after PN. Due to low numbers, clinical T2a and T2b tumors were 
combined as a single category in subgroup analysis, though the HR for all-cause 
mortality due to PSM in this newly formed category still did not achieve statistical 
significance. 
To the best of our knowledge, our study has the largest matched groups to determine 
the impact of PSM on OS after PN. However, it is not without limitations. Like any other 
studies based on a retrospective dataset, our findings were vulnerable to any 
inaccuracies in the NCDB. Statistical matching only accounted for covariates available 
in the NCDB, and confounding could still occur from various unknown clinical factors. 
While propensity score matching helped to reduce selection bias and confounding, a 
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large number of patients with NSM were excluded after matching, significantly reducing 
the effects of the matched covariates on OS. This is probably the reason that our Cox 
multiple regression model did not produce statistically significant HRs for gender, race, 
tumor grade and certain categories of CCI, tumor size and histology, while that by 
Maurice MJ et al showed some of these covariates as significant factors impacting 
OS.10 However, since the primary goal of our study is to determine the effect of PSM on 
OS, this did not weaken the validity of our conclusion. Longer follow-ups would also be 
ideal when studying OS after PN, as the number of mortality in the entire matched 
cohort up to 140 months of follow-up was low (386 deaths in 2530 patients). 
 
Conclusions 
Our study found that PSM is associated with worse OS after PN, at 72.6 month median 
follow-up. It emphasized the clinical importance to maintain a low PSM rate in PN, 
despite various studies showing conflicting results regarding the impact of PSM on 
progression-free and cancer-specific survivals. 
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Tables and Figures 
Figure 1. Diagram showing the process of patient selection for propensity score 
matching. (RCC: renal cell carcinoma, ICD-O-3: International Classification of Diseases 
for Oncology, 3rd Edition, NCDB: National Cancer Database, PUF: participant user file, 
AJCC: American Joint Committee on Cancer, PN: partial nephrectomy, PSM: positive 
surgical margins, NSM: negative surgical margins) 
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Table 1. Descriptive statistics before and after propensity score matching, shown as 
absolute number (percentage). (PSM: positive surgical margins, NSM: negative surgical 
margins, φC: Cramer’s V values, CCI: Charlson-Deyo comorbidity score) 
 Before propensity score matching After propensity score matching 
 PSM 
(n=1278) 
NSM 
(n=19484) 
φC p-value PSM 
(n=1265) 
NSM 
(n=1265) 
φC p-
value 
Age 
(year) 
< 50 262 (20.5%) 4801 (24.6%) 0.036 <0.001 260 (20.6%) 260 (20.6%) 0 1.000 
50 – 59 332 (26.0%) 5323 (27.3%) 331 (26.2%) 331 (26.2%) 
60 – 69 377 (29.5%) 5497 (28.2%) 374 (29.6%) 374 (29.6%) 
70 – 79 242 (18.9%) 3235 (16.6%) 238 (18.8%) 238 (18.8%) 
≥ 80 65 (5.1%) 628 (3.2%) 62 (4.9%) 62 (4.9%) 
Gender Male 816 (63.8%) 11929 (61.2%) 0.013 0.062 808 (63.9%) 788 (62.3%) 0.016 0.410 
Female 462 (36.2%) 7555 (38.8%) 457 (36.1%) 477 (37.7%) 
Race White 1017 (79.6%) 15650 (80.3%) 0.013 0.497 1007 (79.6%) 995 (78.7%) 0.036 0.521 
Black 148 (11.6%) 2026 (10.4%) 146 (11.5%) 137 (10.8%) 
Hispanic 62 (4.9%) 1044 (5.4%) 62 (4.9%) 74 (5.8%) 
Others 30 (2.3%) 504 (2.6%) 30 (2.4%) 41 (3.2%) 
Unknown 21 (1.6%) 260 (1.3%) 20 (1.6%) 18 (1.4%) 
CCI 0 891 (69.7%) 14169 (72.7%) 0.018 0.037 887 (70.1%) 887 (70.1%) 0 1.000 
1 292 (22.8%) 4130 (21.2%) 290 (22.9%) 290 (22.9%) 
≥ 2 95 (7.4%) 1185 (6.1%) 88 (7.0%) 88 (7.0%) 
Tumor 
size (cm) 
≤ 4 1062 (83.1%) 16094 (82.6%) 0.009 0.771 1059 (83.7%) 1059 (83.7%) 0 1.000 
> 4 – ≤ 7 186 (14.6%) 2842 (14.6%) 181 (14.3%) 181 (14.3%) 
> 7 – ≤ 10 20 (1.6%) 376 (1.9%) 19 (1.5%) 19 (1.5%) 
> 10 4 (0.3%) 95 (0.5%) 2 (0.2%) 2 (0.2%) 
Unknown 6 (0.5%) 77 (0.4%) 4 (0.3%) 4 (0.3%) 
Histology Clear cell 866 (67.8%) 14632 (75.1%) 0.044 <0.001 865 (68.4%) 865 (68.4%) 0 1.000 
Papillary 254 (19.9%) 3169 (16.3%) 252 (19.9%) 252 (19.9%) 
Chromophobe 114 (8.9%) 1137 (5.8%) 108 (8.5%) 108 (8.5%) 
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Collecting duct 0 17 (0.1%) 0 0 
Sarcomatoid 3 (0.2%) 39 (0.2%) 2 (0.2%) 2 (0.2%) 
Others 41 (3.2%) 490 (2.5%) 38 (3.0%) 38 (3.0%) 
Fuhrman 
grade 
1 – 2 857 (67.1%) 13638 (70.0%) 0.023 0.005 852 (67.4%) 852 (67.4%) 0 1.000 
3 – 4 283 (22.1%) 3604 (18.5%) 278 (22.0%) 278 (22.0%) 
Unknown 138 (10.8%) 2242 (11.5%) 135 (10.7%) 135 (10.7%) 
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Table 2. Multivariate logistic regression estimating the ORs of PSM among the various 
categories of covariates before propensity score matching. (PSM: positive surgical 
margins, CCI: Charlson-Deyo comorbidity score, OR: odds ratio, CI: confidence interval, 
Ref: reference) 
  OR for PSM 95% CI p-value 
Age (year) < 50 1.0 (Ref)   
50 – 59 1.101 0.930 – 1.302 0.263 
60 – 69 1.188 1.007 – 1.401 0.041 
70 – 79 1.294 1.077 – 1.556 0.006 
≥ 80 1.800 1.350 – 2.401 <0.001 
Gender Male 1.0 (Ref)   
Female 0.915 0.812 – 1.032 0.148 
Race White 1.0 (Ref)   
Black 1.088 0.907 – 1.305 0.363 
Hispanic 0.984 0.755 – 1.284 0.906 
Others 0.940 0.646 – 1.367 0.745 
Unknown 1.285 0.819 – 2.015 0.276 
CCI 0 1.0 (Ref)   
1 1.101 0.958 – 1.264 0.175 
≥ 2 1.242 0.995 – 1.552 0.056 
Tumor size (cm) ≤ 4 1.0 (Ref)   
> 4 – ≤ 7 0.910 0.773 – 1.072 0.259 
> 7 – ≤ 10 0.711 0.450 – 1.122 0.143 
> 10 0.572 0.209 – 1.562 0.275 
Unknown 1.175 0.509 – 2.711 0.705 
Histology Clear cell 1.0 (Ref)   
Papillary 1.299 1.118 – 1.509 0.001 
Chromophobe 1.756 1.422 – 2.167 <0.001 
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Collecting duct 0 0 0.998 
Sarcomatoid 1.274 0.392 – 4.148 0.687 
Others 1.359 0.979 – 1.887 0.066 
Fuhrman grade 1 – 2 1.0 (Ref)   
3 – 4 1.185 1.028 – 1.366 0.019 
Unknown 0.868 0.717 – 1.051 0.147 
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Table 3. Cox multiple regression estimating the HRs for all-cause mortality among the 
various categories of covariates after propensity score matching. (NSM: negative 
surgical margins, PSM: positive surgical margins, CCI: Charlson-Deyo comorbidity 
score, HR: hazard ratio, CI: confidence interval, Ref: reference) 
  HR for all-cause 
mortality 
95% CI p-value 
Margin status NSM 1.0 (Ref)   
PSM 1.393 1.138 – 1.705 0.001 
Age (year) < 50 1.0 (Ref)   
50 – 59 2.341 1.422 – 3.854 0.001 
60 – 69 4.027 2.525 – 6.423 <0.001 
70 – 79 6.721 4.214 – 10.720 <0.001 
≥ 80 13.880 8.359 – 23.048 <0.001 
Gender Male 1.0 (Ref)   
Female 0.839 0.675 – 1.044 0.116 
Race White 1.0 (Ref)   
Black 1.176 0.842 – 1.641 0.341 
Hispanic 1.095 0.678 – 1.769 0.710 
Others 0.888 0.454 – 1.739 0.729 
Unknown 0.567 0.181 – 1.771 0.329 
CCI 0 1.0 (Ref)   
1 1.165 0.917 – 1.480 0.211 
≥ 2 2.384 1.766 – 3.218 <0.001 
Tumor size (cm) ≤ 4 1.0 (Ref)   
> 4 – ≤ 7 1.592 1.237 – 2.049 <0.001 
> 7 – ≤ 10 2.639 1.396 – 4.990 0.003 
> 10 3.548 0.490 – 25.710 0.210 
Unknown 0.000 0 – 1.008x1091 0.931 
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Histology Clear cell 1.0 (Ref)   
Papillary 0.719 0.544 – 0.949 0.020 
Chromophobe 0.341 0.200 – 0.580 <0.001 
Sarcomatoid 1.724 0.238 – 12.473 0.590 
Others 0.648 0.332 – 1.264 0.203 
Fuhrman grade 1 – 2 1.0 (Ref)   
3 – 4 1.050 0.822 – 1.342 0.694 
Unknown 1.515 1.095 – 2.097 0.012 
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Figure 2. Kaplan-Meier curves showing OS stratified by surgical margin status. (PSM: 
positive surgical margins, NSM: negative surgical margins) 
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Table 4. Subgroup analyses estimating the HRs for all-cause mortality between PSM 
and NSM among patients with specific age, CCI, tumor size, histology and grade. (PSM: 
positive surgical margins, NSM: negative surgical margins, CCI: Charlson-Deyo 
comorbidity score, CI: confidence interval, Ref: reference) 
  HR for all-cause 
mortality due to 
PSM (Ref = 1.0 
NSM) 
95% CI p-value 
Age (year) < 50 0.746 0.304 – 1.835 0.524 
50 – 59 1.407 0.837 – 2.366 0.197 
60 – 69 1.136 0.795 – 1.624 0.485 
70 – 79 1.559 1.082 – 2.244 0.017 
≥ 80 1.969 1.109 – 3.497 0.021 
CCI 0 1.065 0.823 – 1.379 0.632 
1 2.395 1.565 – 3.667 <0.001 
≥ 2 1.414 0.812 – 2.463 0.221 
Tumor size (cm) ≤ 4 1.384 1.098 – 1.744 0.006 
> 4 – ≤ 7 1.241 0.786 – 1.959 0.354 
> 7 4.829 0.781 – 29.849 0.090 
Histology Clear cell 1.423 1.129 – 1.793 0.003 
Papillary 1.335 0.809 – 2.204 0.258 
Chromophobe 0.788 0.270 – 2.300 0.663 
Grade 1 – 2 1.365 1.061 – 1.756 0.015 
3 – 4 1.779 1.150 – 2.750 0.010 
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